AMT IIa - Phase II clinical trial to evaluate the efficacy and safety in patients with advanced primary HCC.

Investigational product: Auron Misheil Therapie (AMT2003)

Indication: advanced liver cancer

Study design: prospective, open, multicenter

Important criteria:

Inclusion:  At least one measurable lesion,  Life expectancy at least 3 months

Exclusion: Known secondary neoplasia or central nervous system (CNS) metastases, acute or chronic leukemia, lymphoma or multiple myeloma, Body weight below 45 kg, Concurrent severe or uncontrolled medical disease,  abnormal glucose tolerance test /latent diabetes mellitus type I or II, Chemotherapy, radiotherapy or other clinical tirasl less than 4 weeks prior to entry, Surgery less than 2 weeks prior to entry (or not recovered from effects of surgery).

Study physician at SanaFontis: PD. Dr. med. J. Drevs (PI)

Status: ongoing

Further information:

Medical Information Service

Tel.:  +49 (0761) 888 59-58 74
Fax:  +49 (0761) 888 59-59 57

E-Mail: medinfo(at)sanafontis.com